These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 28216278)

  • 1. Outcomes of Patients With Metastatic Renal Cell Carcinoma and Bone Metastases in the Targeted Therapy Era.
    Kalra S; Verma J; Atkinson BJ; Matin SF; Wood CG; Karam JA; Lin SH; Satcher RL; Tamboli P; Sircar K; Rao P; Corn PG; Tannir NM; Jonasch E
    Clin Genitourin Cancer; 2017 Jun; 15(3):363-370. PubMed ID: 28216278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cabozantinib in the treatment of metastatic renal cell carcinoma - final data analysis from four oncology centers in the Czech Republic.
    Richter I; Poprach A; Zemánková A; Büchler T; Bartoš J; Šámal V; Študentová H; Rozsypalová A; Dvořák J; Brom O; Melichar B
    Klin Onkol; 2021; 34(5):392-400. PubMed ID: 34915708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spine stereotactic radiosurgery with concurrent tyrosine kinase inhibitors for metastatic renal cell carcinoma.
    Miller JA; Balagamwala EH; Angelov L; Suh JH; Rini B; Garcia JA; Ahluwalia M; Chao ST
    J Neurosurg Spine; 2016 Dec; 25(6):766-774. PubMed ID: 27391397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Whole-body diffusion-weighted magnetic resonance imaging for the detection of bone metastases and their prognostic impact in metastatic renal cell carcinoma patients treated with angiogenesis inhibitors.
    Beuselinck B; Pans S; Bielen J; De Wever L; Noppe N; Vanderschueren G; De Keyzer F; Baldewijns M; Lerut E; Laenen A; Verbiest A; Roussel E; Albersen M; Vandecaveye V
    Acta Oncol; 2020 Jul; 59(7):818-824. PubMed ID: 32297532
    [No Abstract]   [Full Text] [Related]  

  • 5. Absence of Significant Correlation of Adverse Events Between First- and Second-Line Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma.
    Miyake H; Imai S; Harada K; Fujisawa M
    Clin Genitourin Cancer; 2016 Feb; 14(1):e19-24. PubMed ID: 26382221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of tyrosine kinase inhibitors on the multimodality treatment of brain metastases from renal cell carcinoma.
    Verma J; Jonasch E; Allen PK; Weinberg JS; Tannir N; Chang EL; Mahajan A
    Am J Clin Oncol; 2013 Dec; 36(6):620-4. PubMed ID: 22892430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of tyrosine kinase inhibitors on the incidence of brain metastasis in metastatic renal cell carcinoma.
    Verma J; Jonasch E; Allen P; Tannir N; Mahajan A
    Cancer; 2011 Nov; 117(21):4958-65. PubMed ID: 21484781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitors.
    Santoni M; Conti A; Partelli S; Porta C; Sternberg CN; Procopio G; Bracarda S; Basso U; De Giorgi U; Derosa L; Rizzo M; Ortega C; Massari F; Iacovelli R; Milella M; Di Lorenzo G; Buti S; Cerbone L; Burattini L; Montironi R; Santini D; Falconi M; Cascinu S
    Ann Surg Oncol; 2015; 22(6):2094-100. PubMed ID: 25472645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon treatment for Japanese patients with favorable-risk metastatic renal cell carcinoma in the era of targeted therapy.
    Sazuka T; Nihei N; Nakamura K; Sakamoto S; Fukasawa S; Komaru A; Ueda T; Igarashi T; Ichikawa T
    Korean J Urol; 2015 Mar; 56(3):205-11. PubMed ID: 25763124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognosis of renal cell carcinoma with bone metastases: Experience from a large cancer centre.
    Ruatta F; Derosa L; Escudier B; Colomba E; Guida A; Baciarello G; Loriot Y; Fizazi K; Albiges L
    Eur J Cancer; 2019 Jan; 107():79-85. PubMed ID: 30551078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. No Significant Correlation of Clinical Outcomes Between First- and Second-line Tyrosine Kinase Inhibitors in Patients with Metastatic Renal Cell Carcinoma.
    Miyazaki A; Miyake H; Harada K; Fujisawa M
    Anticancer Res; 2015 May; 35(5):3067-73. PubMed ID: 25964597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognosis of patients with metastatic renal cell carcinoma and pancreatic metastases.
    Kalra S; Atkinson BJ; Matrana MR; Matin SF; Wood CG; Karam JA; Tamboli P; Sircar K; Rao P; Corn PG; Tannir NM; Jonasch E
    BJU Int; 2016 May; 117(5):761-5. PubMed ID: 26032863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world outcomes in metastatic renal cell carcinoma: insights from a Joint Community-Academic Registry.
    Harrison MR; Hirsch BR; George DJ; Walker MS; Chen C; Korytowsky B; Stepanski E; Abernethy AP
    J Oncol Pract; 2014 Mar; 10(2):e63-72. PubMed ID: 24281152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progression free survival of first line vascular endothelial growth factor-targeted therapy is an important prognostic parameter in patients with metastatic renal cell carcinoma.
    Seidel C; Busch J; Weikert S; Steffens S; Fenner M; Ganser A; Grünwald V
    Eur J Cancer; 2012 May; 48(7):1023-30. PubMed ID: 22436979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of degree of hypothyroidism with survival outcomes in patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor receptor tyrosine kinase inhibitors.
    Bailey EB; Tantravahi SK; Poole A; Agarwal AM; Straubhar AM; Batten JA; Patel SB; Wells CE; Stenehjem DD; Agarwal N
    Clin Genitourin Cancer; 2015 Jun; 13(3):e131-7. PubMed ID: 25497584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does the onset of bone metastasis in sunitinib-treated renal cell carcinoma patients impact the overall survival?
    Ivanyi P; Koenig J; Trummer A; Busch JF; Seidel C; Reuter CW; Ganser A; Grünwald V
    World J Urol; 2016 Jul; 34(7):909-15. PubMed ID: 26586475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Benefit of Everolimus as Second-Line Therapy in Metastatic Renal Cell Carcinoma: The French Retrospective SECTOR Study.
    Oudard S; Joly F; Geoffrois L; Laguerre B; Houede N; Barthelemy P; Gross-Goupil M; Vano Y; Lucidarme O; Bidault F; Kelkouli N; Slimane K; Escudier B
    Clin Genitourin Cancer; 2016 Dec; 14(6):e595-e607. PubMed ID: 27283478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overall survival after immunotherapy, tyrosine kinase inhibitors and surgery in treatment of metastatic renal cell cancer: outcome of 143 consecutive patients from a single centre.
    De Lichtenberg TH; Hermann GG; Rørth M; Højer Larsen MJ; Mansourvar Z; Holm ML; Scheike T
    Scand J Urol; 2014 Aug; 48(4):379-86. PubMed ID: 24521185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Tyrosine Kinase Inhibitor
    Miyake H; Imai S; Tamura K; Sugiyama T; Furuse H; Ozono S; Fujisawa M
    Anticancer Res; 2017 Mar; 37(3):1523-1528. PubMed ID: 28314328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) rechallenge for patients with metastatic renal cell carcinoma after treatment failure using both VEGFR-TKI and mTOR inhibitor.
    Park I; Lee JL; Ahn JH; Lee DH; Lee KH; You D; Jeong IG; Song C; Hong B; Hong JH; Ahn H
    Cancer Chemother Pharmacol; 2015 May; 75(5):1025-35. PubMed ID: 25776906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.